论文部分内容阅读
应用免疫组织化学ＢＡ法探讨了１２３例乳腺癌患者预后与雌激素受体（ＥＲ）的关系。平均随访７２个月（２个月～１１２个月）。结果显示ＥＲ（＋）８８例，术后复发转移１９例，占２１．６％，５年生存率７４．４％，ＥＲ（－）组３５例，术后转移复发１５例，占４２．９％，５年生存率５２．３％。经统计学处理有显著性差异。提示ＥＲ（－）乳腺癌属相对高危组，预后差，术后复发转移率高，５年生存率低，ＥＲ（＋）患者属相对低危组，其预后明显好于ＥＲ（－）组。
The relationship between prognosis and estrogen receptor (ER) in 123 breast cancer patients was studied by immunohistochemical BA method. The average follow-up period was 72 months (2 months to 112 months). The results showed 88 cases of ER (+), postoperative recurrence and metastasis in 19 cases, accounting for 21.6%, 5-year survival rate of 74.4%, ER (-) group of 35 cases, postoperative metastasis and recurrence of 15 cases, accounting for 42.9 %, 5-year survival rate 52.3%. Statistically significant differences. The ER (-) breast cancer is relatively high-risk group, poor prognosis, postoperative recurrence and metastasis rate, low 5-year survival rate, ER (+) patients are relatively low-risk group, its prognosis is significantly better than ER (-) group.